GSK plc (GLAXF)
| Previous Close | 21.14 |
| Open | 22.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 22.00 - 22.04 |
| 52 Week Range | 16.65 - 22.14 |
| Volume | |
| Avg. Volume | 1,308 |
| Market Cap | 92.394B |
| Beta (5Y Monthly) | 0.27 |
| PE Ratio (TTM) | 16.08 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.75 (3.56%) |
| Ex-Dividend Date | May 16, 2024 |
| 1y Target Est | N/A |
- GlobeNewswire
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Round by CHF 12.3 Million
Strategic collaboration with GSK expanded to accelerate clinical development of alpibectir for the treatment of tuberculosisGSK to participate in Series C Extension with equity investmentSeries C financing round extended overall by CHF 12.3 million to CHF 44.9 million BASEL, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections
- CNW Group
University of Toronto scientists appointed as GSK chairs will advance drug delivery research and vaccine education tools for healthcare professionals
The University of Toronto's Leslie Dan Faculty of Pharmacy has announced the appointments of two leading scientists as endowed GSK research chairs. These appointments represent the collaborative efforts between the two organizations to advance the field of pharmacy and drive positive change in patient care.
- CNW Group
GSK Canada expands charitable partnerships to include support of environmental sustainability and STEM
GSK is proud to announce new charitable partnerships in STEM (science, technology, engineering and math) education for underrepresented communities and environmental sustainability. The company's newest philanthropic collaborations are an exciting opportunity to support our commitment to the health of our planet and the next generation of scientists in an equal and inclusive manner.
